Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Chemotherapy
56%
Immune Checkpoint Inhibitor
47%
Epidermal Growth Factor Receptor
44%
Progression Free Survival
35%
Overall Survival
32%
Osimertinib
30%
Programmed Death 1 Ligand 1
29%
Lung Cancer
26%
Monotherapy
23%
Pembrolizumab
19%
Neoplasm
17%
Retrospective Study
16%
Paclitaxel
15%
Afatinib
15%
Carboplatin
14%
Immunotherapy
14%
Docetaxel
13%
Pemetrexed
12%
Epidermal Growth Factor Receptor Kinase Inhibitor
10%
Programmed Cell Death
10%
Combination Therapy
10%
Cohort Study
9%
Homeobox Protein Nkx 2.1
8%
Malignant Neoplasm
8%
Cachexia
7%
Pleura Mesothelioma
7%
Nivolumab
7%
Disease
6%
Biological Marker
6%
Clinical Trial
6%
Adverse Event
6%
Bevacizumab
6%
Atezolizumab
6%
Observational Study
6%
Survival Rate
5%
Pneumonia
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
73%
Chemoimmunotherapy
35%
Immune Checkpoint Inhibitor
35%
Retrospective Study
23%
Programmed Death 1 Ligand 1
22%
Epidermal Growth Factor Receptor
22%
Overall Survival
21%
Progression Free Survival
21%
Monotherapy
21%
Lung Cancer
15%
Osimertinib
14%
Epidermal Growth Factor Receptor Kinase Inhibitor
13%
Immunotherapy
13%
Neoplasm
12%
Pembrolizumab
12%
Combination Therapy
11%
Endobronchial Ultrasonography
10%
Transbronchial Biopsy
10%
Programmed Cell Death
10%
Non-Small Cell Lung Cancer
9%
Cohort Analysis
8%
Prognostic Factor
8%
Homeobox Protein Nkx 2.1
8%
Lung
7%
Programmed Cell Death
7%
Cachexia
7%
Liver Metastasis
6%
Biological Marker
6%
Bevacizumab
6%
Carboplatin
6%
Paclitaxel
6%
Atezolizumab
6%
Squamous Cell Carcinoma
5%
Maintenance Therapy
5%
Programmed Death-Ligand 1
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
56%
Immune Checkpoint Inhibitors
36%
Programmed Death-ligand 1 (PD-L1)
32%
Chemotherapy
31%
Chemoimmunotherapy
28%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
28%
Monotherapy
19%
Overall Survival
18%
Progression-free Survival
16%
Confidence Interval
16%
Pembrolizumab
16%
Epidermal Growth Factor Receptor
16%
Programmed Death-ligand 1 Expression
14%
Tumor Proportion Score
11%
Japan
8%
Osimertinib
8%
EGFR mutation
8%
Pemetrexed
8%
Treatment Outcome
8%
Phase II Trial
8%
Previously Treated
7%
Pulmonary Pleomorphic Carcinoma
7%
Older Patients
7%
Thyroid Transcription factor-1 (TTF-1)
7%
Multicenter Retrospective Study
7%
Carboplatin
7%
Non-small Cell Lung Cancer Patients
6%
Clinical Factors
6%
Docetaxel
6%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
5%
Combination Therapy
5%
Hazard Ratio
5%
No Significant Difference
5%